Oxidative stress contributes to the impaired sonic hedgehog pathway in type 1 diabetic mice with myocardial infarction

Xiao,Qing; Yang,Ya; Zhao,Xiao-Ya; He,Li‑Shan; Qin,Yuan; He,Yan‑Hua; Zhang,Gui‑Ping; Luo,Jian‑Dong

doi:10.3892/etm.2015.2766

Oxidative stress contributes to the impaired sonic hedgehog pathway in type 1 diabetic mice with myocardial infarction

Authors:
- Qing Xiao
- Ya Yang
- Xiao-Ya Zhao
- Li‑Shan He
- Yuan Qin
- Yan‑Hua He
- Gui‑Ping Zhang
- Jian‑Dong Luo
View Affiliations

Affiliations: Department of Pharmacology, Guangzhou Medical University, Guangzhou, Guangdong 510182, P.R. China, Guangzhou Research Institute of Snake Venom, Guangzhou Medical University, Guangzhou, Guangdong 510182, P.R. China
Published online on: September 23, 2015 https://doi.org/10.3892/etm.2015.2766
Pages: 1750-1758
Copyright: © Xiao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our previous study demonstrated that an impaired sonic hedgehog (Shh) pathway contributed to cardiac dysfunction in type 1 diabetic mice with myocardial infarction (MI). The present study aimed to test the hypothesis that oxidative stress may contribute to the impaired Shh pathway and cardiac dysfunction in type 1 diabetic mice with MI. Streptozotocin‑induced type 1 diabetic mice (C57/Bl6, male) and rat neonatal cardiomyocytes were used in the present study. Mice were randomly assigned to undergo ligation of the coronary artery or pseudosurgery. A potent antioxidant Tempol was administered in vivo and in vitro. Cardiac function was assessed by echocardiography, capillary density by immunohistochemisty, percentage of myocardial infarct using Masson's trichrome staining, reactive oxygen species detection using dihydroethidium dye or 2',7'‑dichlorofluorescein diacetate probe and protein expression levels of the Shh pathway by western blot analysis. The antioxidant Tempol was shown to significantly increase myocardial protein expression levels of Shh and patched‑1 (Ptc1) at 7‑18 weeks and improved cardiac function at 18 weeks in type 1 diabetic mice, as compared with mice receiving no drug treatment. Furthermore, myocardial protein expression levels of Shh and Ptc1 were significantly upregulated on day 7 after MI, and capillary density was enhanced. In addition, the percentage area of myocardial infarct was reduced, and the cardiac dysfunction and survival rate were improved on day 21 in diabetic mice treated with Tempol. In vitro, treatment of rat neonatal cardiomyocytes with a mixture of xanthine oxidase and xanthine decreased protein expression levels of Shh and Ptc1 in a concentration‑dependent manner, and Tempol attenuated this effect. These results indicate that oxidative stress may contribute to an impaired Shh pathway in type 1 diabetic mice, leading to diminished myocardial healing and cardiac dysfunction. Antioxidative strategies aimed at restoring the endogenous Shh pathway may offer a useful means for improving diabetic cardiac function.

View Figures

View References

1	Krum H and Gilbert RE: Demographics and concomitant disorders in heart failure. Lancet. 362:147–158. 2003. View Article : Google Scholar : PubMed/NCBI
2	Marfella R, Filippo CD, Portoghese M, Siniscalchi M, Martis S, Ferraraccio F, Gustafierro S, Nicoletti G, Barbieri M, Coppola A, et al: The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: The role of glycemic control. Cardiovasc Pathol. 18:332–345. 2009. View Article : Google Scholar : PubMed/NCBI
3	Shishido T, Woo CH, Ding B, McClain C, Molina CA, Yan C, Yang J and Abe J: Effects of MEK5/ERK5 association on small ubiquitin-related modification of ERK5: Implications for diabetic ventricular dysfunction after myocardial infarction. Circ Res. 102:1416–1425. 2008. View Article : Google Scholar : PubMed/NCBI
4	Bucciarelli LG, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, Strauch C, Monnier VM, Yan SF, Schmidt AM and Ramasamy R: RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes. 57:1941–1951. 2008. View Article : Google Scholar : PubMed/NCBI
5	Samuel SM, Thirunavukkarasu M, Penumathsa SV, Koneru S, Zhan L, Maulik G, Sudhakaran PR and Maulik N: Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation. 121:1244–1255. 2010. View Article : Google Scholar : PubMed/NCBI
6	Di Filippo C, Marfella R, Cuzzocrea S, Piegari E, Petronella P, Giugliano D, Rossi F and D'Amico M: Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes. 54:803–810. 2005. View Article : Google Scholar : PubMed/NCBI
7	Marfella R, D'Amico M, Di Filippo C, Piegari E, Nappo F, Esposito K, Berrino L, Rossi F and Giugliano D: Myocardial infarction in diabetic rats: Role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia. 45:1172–1181. 2002. View Article : Google Scholar : PubMed/NCBI
8	Mimeault M and Batra SK: Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies. Pharmacol Rev. 62:497–524. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lewis PM, Dunn MP, McMahon JA, Logan M, Martin JF, St-Jacques B and McMahon AP: Cholesterol modification of sonic hedgehog is required for long-range signaling activity and effective modulation of signaling by Ptc1. Cell. 105:599–612. 2001. View Article : Google Scholar : PubMed/NCBI
10	Chari NS and McDonnell TJ: The sonic hedgehog signaling network in development and neoplasia. Adv Anat Pathol. 14:344–352. 2007. View Article : Google Scholar : PubMed/NCBI
11	Varjosalo M and Taipale J: Hedgehog signaling. J Cell Sci. 120:3–6. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kusano KF, Pola R, Murayama T, Curry C, Kawamoto A, Iwakura A, Shintani S, Ii M, Asai J, Tkebuchava T, et al: Sonic hedgehog myocardial gene therapy: Tissue repair through transient reconstitution of embryonic signaling. Nat Med. 11:1197–1204. 2005. View Article : Google Scholar : PubMed/NCBI
13	Ueda K, Takano H, Niitsuma Y, Hasegawa H, Uchiyama R, Oka T, Miyazaki M, Nakaya H and Komuro I: Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest. 120:2016–2029. 2010. View Article : Google Scholar : PubMed/NCBI
14	Xiao Q, Hou N, Wang YP, He LS, He YH, Zhang GP, Yi Q, Liu SM, Chen MS and Luo JD: Impaired sonic hedgehog pathway contributes to cardiac dysfunction in type 1 diabetic mice with myocardial infarction. Cardiovas Res. 95:507–516. 2012. View Article : Google Scholar
15	Giacco F and Brownlee M: Oxidative stress and diabetic complications. Circ Res. 107:1058–1070. 2010. View Article : Google Scholar : PubMed/NCBI
16	Newsholme P, Haber EP, Hirabara SM, Rebelato EL, Procopio J, Morgan D, Oliviera-Emilio HC, Carpinelli AR and Curi R: Diabetes associated cell stress and dysfunction: Role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol. 583:9–24. 2007. View Article : Google Scholar : PubMed/NCBI
17	Martinon F: Signaling by ROS drives inflammasome activation. Eur J Immunol. 40:616–619. 2010. View Article : Google Scholar : PubMed/NCBI
18	Wang Y and Tabas I: Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association? J Atheroscler Thromb. 21:381–390. 2014. View Article : Google Scholar : PubMed/NCBI
19	Sabharwal SS and Schumacker PT: Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles heel? Nat Rev Cancer. 14:709–721. 2014. View Article : Google Scholar : PubMed/NCBI
20	de Vries HE, Witte M, Hondius D, Rozemuller AJ, Drukarch B, Hoozemans J and van Horssen J: Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radic Biol Med. 45:1375–1383. 2008. View Article : Google Scholar : PubMed/NCBI
21	Pennathur S and Heinecke JW: Mechanisms for oxidative stress in diabetic cardiovascular disease. Antioxid Redox Signal. 9:955–969. 2007. View Article : Google Scholar : PubMed/NCBI
22	Hou N, Luo MS, Liu SM, Zhang HN, Xiao Q, Sun P, Zhang GS, Luo JD and Chen MS: Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor α pathway in cultured neonatal rat cardiomyocytes. Clin Exp Pharmacol Physiol. 37:1087–1095. 2010. View Article : Google Scholar : PubMed/NCBI
23	Khullar M, Al-Shudiefat AA, Ludke A, Binepal G and Singal PK: Oxidative stress: A key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol. 88:233–240. 2010. View Article : Google Scholar : PubMed/NCBI
24	Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, Zuppi C and Ghirlanda G: Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 7:15–25. 2010. View Article : Google Scholar : PubMed/NCBI
25	Wilcox CS: Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther. 126:119–145. 2010. View Article : Google Scholar : PubMed/NCBI
26	Jiang Q: Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med. 72:76–90. 2014. View Article : Google Scholar : PubMed/NCBI
27	Danta CC and Piplani P: The discovery and development of new potential antioxidant agents for the treatment of neurodegenerative diseases. Expert Opin Drug Discov. 9:1205–1222. 2014. View Article : Google Scholar : PubMed/NCBI
28	Feng Y and Wang X: Antioxidant therapies for Alzheimers disease. Oxid Med Cell Longev. 2012:2012. View Article : Google Scholar : PubMed/NCBI
29	Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN and Hensley K: Antioxidants in central nervous system diseases: Preclinical promise and translational challenges. J Alzheimers Dis. 15:473–493. 2008.PubMed/NCBI
30	Boodhwani M and Sellke FW: Therapeutic angiogenesis in diabetes and hypercholesterolemia: Influence of oxidative stress. Antioxid Redox Signal. 11:1945–1959. 2009. View Article : Google Scholar : PubMed/NCBI
31	Napoli C, Williams-Ignarro S, de Nigris F, de Rosa G, Lerman LO, Farzati B, Matarazzo A, Sica G, Botti C, Fiore A, et al: Beneficial effects of concurrent autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the mouse hindlimb. Proc Natl Acad Sci USA. 102:17202–17206. 2005. View Article : Google Scholar : PubMed/NCBI